



SMA Screening System Using Dried Blood Spots on Filter Paper: Application of C0P-PCR to the SMN1 Deletion Test

Kato, Nozomu ; Sa'adah, Nihayatus ; Rochmah, Mawaddah Ar ; Harahap, Nur Imma Fatimah ; Nurputra, Dian Kesumapramudya ; Sato, Hideyuki ; Sadewa...

(Citation)

The Kobe journal of the medical sciences, 60(4):78-85

(Issue Date)

2014

(Resource Type)

departmental bulletin paper

(Version)

Version of Record

(JaLCD0I)

<https://doi.org/10.24546/81008730>

(URL)

<https://hdl.handle.net/20.500.14094/81008730>



SMA Screening System Using Dried Blood Spots on Filter Paper: Application of COP-PCR to the *SMN1* Deletion Test

NOZOMU KATO^{1,2}, NIHAYATUS SA'ADAH^{1,3},
MAWADDAH AR ROCHMAH¹, NUR IMMA FATIMAH HARAHAP¹,
DIAN KESUMAPRAMUDYA NURPUTRA¹, HIDEYUKI SATO¹,
AHMAD HAMIM SADEWA^{3,4}, INDWIANI ASTUTI^{3,5},
SOFIA MUBARIKA HARYANA^{3,6}, TOSHIO SAITO⁷,
KAYOKO SAITO⁸, NORIYUKI NISHIMURA¹,
HISAHIDE NISHIO¹ and ATSUKO TAKEUCHI^{2,*}

¹ Department of Community Medicine and Social Healthcare Science,

Kobe University Graduate School of Medicine, Kobe, Japan;

² Kobe Pharmaceutical University, Kobe, Japan;

³ Basic Medical and Biomedical Sciences, Graduate School of Medicine,

Universitas Gadjah Mada, Yogyakarta, Indonesia;

⁴ Department of Biochemistry, Faculty of Medicine,

Universitas Gadjah Mada, Yogyakarta, Indonesia;

⁵ Department of Pharmacology, Faculty of Medicine,

Universitas Gadjah Mada, Yogyakarta, Indonesia;

⁶ Department of Histology and Cell Biology, Faculty of Medicine,

Universitas Gadjah Mada, Yogyakarta, Indonesia;

⁷ Division of Child Neurology, Department of Neurology,

National Hospital Organization Toneyama National Hospital, Toneyama, Japan;

⁸ Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan

Received 20 October 2014/ Accepted 7 November 2014

Keywords: spinal muscular atrophy, *SMN1*, *SMN2*, COP-PCR, dried blood spot

BACKGROUND: Spinal muscular atrophy (SMA) is a common neuromuscular disorder caused by mutations in *SMN1*. More than 95% of SMA patients carry homozygous *SMN1* deletions. Thus, the *SMN1* deletion test should be performed initially as part of the diagnostic process. However, *SMN2*, a highly homologous gene, hampers detection of *SMN1* deletion. To differentiate between *SMN1* and *SMN2*, many analysis methods have been developed yet they are not all available worldwide. **AIM:** To establish a simple but accurate *SMN1*-deletion detection system that can be used worldwide. **METHODS:** Fifty DNA samples (29 SMA patients and 21 controls) from dried blood spots (DBS) on filter paper were assayed. All participants had previously been screened for SMA by PCR-restriction fragment length polymorphism (PCR-RFLP) using DNA extracted from freshly collected blood. DNA was extracted from DBS that had been stored at room temperature (20–25°C) for between 1 and 8 years. Competitive oligonucleotide priming-PCR (COP-PCR) was performed to distinguish *SMN1* and *SMN2* exon7. **RESULTS:** DNA yield from an 11-mm diameter DBS circle was $21,171 \pm 7,485$ ng (mean $\pm$ SD), with an 260/280 OD ratio from 1.49 to 2.1 (mean $\pm$ SD; 1.67 ± 0.13). Nucleotide sequencing confirmed gene-specific amplification of *SMN1* and *SMN2* by COP-PCR. *SMN1* and *SMN2* COP-PCR results are completely consistent with those obtained by PCR-RFLP. **CONCLUSION:** We have combined DNA extraction from DBS on filter paper with COP-PCR that specifically detects *SMN1* and *SMN2*, establishing a new *SMN1*-deletion detection system with practical application worldwide.

INTRODUCTION

Spinal muscular atrophy (SMA) causes general muscle weakness because of a loss of lower motor neurons in the spinal cord. SMA is a common autosomal recessive disorder, with an incidence of 1/10,000 live births [24]. SMA is classified into three subtypes that depends on age of disease onset and achievement of motor milestones [19]: type 1 (severe form; onset age of 0–6 months, unable to sit unaided), type 2 (intermediate form; onset age of <18 months, unable to stand or walk unaided), and type 3 (mild form; onset age of >18 months, able to stand or walk unaided). Additionally, two other forms have been reported, SMA type 0 is the most severe and has a prenatal onset, while SMA type 4 is mildest and manifests after 20 years of age [12].

The gene for SMA, survival motor neuron 1 (*SMN1*), was cloned in 1995. *SMN1* encodes the SMN protein, which plays a critical role in cellular metabolism [22]. More than 95% of SMA patients have homozygous *SMN1* deletions [13], while the rest (< 5%) may carry intragenic *SMN1* mutations or be non-*SMN1*-related SMA (non-5q-SMA) [13]. Thus, at the beginning of diagnosis, *SMN1* deletion tests should be performed.

All SMA patients with homozygous *SMN1* deletions carry at least one copy of the *SMN2* gene, as complete loss of both *SMN* genes causes embryonic lethality [9, 27]. *SMN2* is highly homologous to *SMN1*, with only five nucleotide differences between them [11], and *SMN2* also produces a small amount of SMN protein [14]. The presence of *SMN2* may compensate for loss of *SMN1* to some degree, and higher copy numbers of *SMN2* are correlated with milder SMA phenotypes [3,7,15,29,31]. However, with regard to diagnosis or screening by conventional PCR methods, *SMN2* hampers detection of homozygous *SMN1* deletion.

To address this problem, various unique PCR methods have been established, for example, PCR and single-strand conformation polymorphism (PCR-SSCP) [13], PCR and restriction fragment length polymorphism (PCR-RFLP) [30], radio-isotope competitive PCR [15], PCR and denaturing high-performance liquid chromatography (DHPLC) [28], real-time PCR [4], multiplex ligation probe amplification (MLPA) [1], tetra-primer PCR [2], and high-resolution melting analysis [18]. However, not one of these methods can be readily introduced into all laboratories, some require expensive equipment or special reagents (e.g. radioisotopes), while others require much effort and are time-consuming procedures. Thus, further research is needed for the innovation of new simpler methods for distinguishing between *SMN1* and *SMN2*. We previously found that competitive oligonucleotide priming-PCR (COP-PCR) can separately amplify *SMN1* and *SMN2* [21], with each of the genes specifically amplified as usual by PCR.

In addition, when considering molecular analysis of any disease (including SMA), it should be noted that the capability to perform molecular analyses are not universally available in all geographical regions of the world. If simple method of collection, storage, and transfer of samples can be established, all patients will gain access to the benefits of molecular analysis regardless of geographical or industrial limitations [8]. We have previously reported that dried blood spots (DBS) on filter paper, which can be sent by mail, are a good DNA source for SMA diagnosis [8].

In this study, we combined DNA extraction from DBS on filter paper and COP-PCR analysis to establish a simple but accurate *SMN1*-deletion detection system that has practical utility in any area of the world. Here, we report on the yield and purity of DNA extracted from DBS, storage year effect on PCR amplification, and specificity of COP-PCR amplification.

MATERIAL AND METHODS

Patient and control samples

Fifty individuals were assayed, 28 SMA patients and 22 controls. All individuals had been previously analyzed by PCR-RFLP using DNA extracted from freshly collected blood [30]. Prior to analysis, informed consent was obtained from study participants. The study was approved by the Ethical Committee of Kobe University Graduate School of Medicine.

DNA extraction from DBS on filter paper

Blood samples were collected from SMA patients and controls using filter paper FTA[®] Elute Cards (Thermo Fisher Scientific, Waltham, MA, USA). Storage periods of blood samples on FTA[®] Elute Cards varied from 1 to 8 years. All FTA[®] Elute Cards were stored in the dark at room temperature (20–25°C). Genomic DNA was extracted from DBS according to our previous report [8]. Here, the protocol is briefly described. To extract DNA from DBS on cards, a hole punch was used to punch out seven 3-mm diameter circles from an 11-mm diameter DBS, equivalent to 50 µL of whole blood. The seven circles were placed into a sterile tube, washed in 500 µL distilled water, and vortexed three times. Washing water was completely removed from the circles, and 75 µL Tris-EDTA Buffer, pH 8.0 (TE buffer) added to the tube. The tube was heated at 95°C for 30 min, and then TE buffer containing DNA eluted and used as a DNA template for PCR or stored at –20°C until use. The

concentration and absorbance ratio of the DNA solution were measured at 260/280 nm (260/280 OD ratio) using a NanoDrop® ND-1000 spectrophotometer (Thermo Fisher Scientific).

COP-PCR for *SMN1*/*SMN2* exon 7

To separately amplify exon 7 from *SMN1* and *SMN2*, we performed COP-PCR using a thermal cycler (Bio-Rad iCycler Thermal Cycler, Bio-Rad Laboratories, Inc., Foster City, CA, USA). The PCR mixture total volume was 30 μ L, consisted of distilled water, genomic DNA template (50–500 ng), 10 pmol/ μ L of common forward primer (R111), 100 pmol/ μ L of gene-specific reverse primer (*SMN1*-COP or *SMN2*-COP), 10 mM dNTP, 10 $\times$ buffer with $MgCl_2$, and Taq DNA polymerase (Fast Start Taq DNA polymerase, Roche Applied Science, Mannheim, Germany). Primer sequences are shown in Fig. 1. After an initial denaturing step of 94°C for 7-min, 30 cycles were performed consisting of 1-min denaturing at 94°C, 1-min annealing at 35°C, and 1-min extension at 72°C, followed by 7-min at 72°C. An aliquot of each COP-PCR product was electrophoresed on a 4% agarose gel with 1 $\times$ TBE buffer, and visualized by ethidium bromide staining.




Fig. 1. Sequences, positions and directions of primers (R111, *SMN1*-COP and *SMN2*-COP). Nucleotides G and A in intron 6, and C and T in exon 7 indicate gene-specific differences between *SMN1* and *SMN2*. The expected sizes of *SMN1*- and *SMN2*-specific products are 168 bp and 169 bp, respectively.

Sequencing of COP-PCR products

Amplified COP-PCR products of *SMN1*/*SMN2* exon 7 were purified and used for cycle sequencing reactions with R111 primer. Cycle sequencing products were directly sequenced using a dye terminator cycle-sequencing kit (Life Technologies Corporation, Carlsbad, CA, USA). Reaction products were electrophoresed on an ABI PRISM® 310 Genetic Analyzer (Life Technologies Corporation).

RESULTS

Extracted DNA yield and storage period of DBS on filter paper

The DNA yield in an 11-mm diameter DBS circle was 21,171 $\pm$ 7,485 ng (mean $\pm$ SD), with 260/280 OD ratio from 1.49 to 2.1 (mean $\pm$ SD; 1.67 $\pm$ 0.13) (Table I).

Table I. DNA yield and 260/280 OD ratio

	DNA samples with good amplification (n=46)	DNA samples with no amplification (n=4)	All DNA samples (n=50)
DNA yield (ng) (11-mm $\varnothing$ DBS circle)	21,564 $\pm$ 7,268	16,650 $\pm$ 8,403	21,171 $\pm$ 7,485
260/280 OD ratio	1.68 $\pm$ 0.13	1.60 $\pm$ 0.06	1.67 $\pm$ 0.13

There were four DNA samples (three controls and one SMA patient) with no COP-PCR amplification of either gene. Non-amplification of both genes is considered a false result, as the combination of *SMN1* and *SMN2* deletion causes embryonic lethality [9,27]. To determine if these four samples were of sufficient quality for PCR, we performed a conventional PCR experiment using a primer set for the *CFTR* gene [15], which resulted in failure of *CFTR* fragment amplification (data not shown). Thus, we concluded that these four samples had deteriorated and were not suitable for PCR amplification, and therefore omitted them from further analysis.

SMA SCREENING WITH COP-PCR USING DRIED BLOOD SPOTS

These four DNA samples had been stored more than 4 years before analysis (Table II). Nevertheless, it should be noted that the DNA concentrations and 260/280 OD ratios of these samples were similar to those showing good amplification with SMN1-COP or SMN2-COP primers (Table I).

Table II. Storage period of DBS on filter paper

Years	0 - 1	2	3	4	5	6	7	8
Samples with amplification	8	6	7	4	9	7	2	3
Samples with non-amplification	0	0	0	1	0	0	1	2

COP-PCR amplification patterns

COP-PCR allowed us to separate *SMN1* exon 7 from *SMN2* exon 7 (Fig. 2). The COP-PCR diagnostic screening results are summarized in Fig. 3.




Fig. 2 COP-PCR amplification patterns. COP-PCR clearly distinguishes three genotypes: *SMN1*(+)/*SMN2*(+) (Pattern 1; *SMN1* and *SMN2* retention), *SMN1* (+)/*SMN2* (-) (Pattern 2; *SMN1* retention and *SMN2* deletion), and *SMN1*(-)/*SMN2* (+) (Pattern 3; *SMN1* deletion and *SMN2* retention).

In 18 controls and two patients with intragenic *SMN1* mutations, COP-PCR using either R111 and *SMN1*-COP or R111 and *SMN2*-COP produced amplification products (Pattern 1 in Figs. 2 and 3). In three controls, COP-PCR using R111 and *SMN1*-COP produced an amplification product, while R111 and *SMN2*-COP produced no amplification product (Pattern 2 in Figs. 2 and 3). In 23 patients with homozygous *SMN1* deletions, COP-PCR using R111 and *SMN1*-COP produced no amplification product, while R111 and *SMN2*-COP produced an amplification product (Pattern 3 in Figs. 2 and 3).




Fig. 3 Summary of the COP-PCR data. Pattern 1 group: 18 control individuals and 2 SMA patients with intragenic *SMN1* mutations. Pattern 2 group: 3 control individuals. Pattern 3 group: 23 SMA patients with homozygous deletions.

To confirm gene-specific amplification by COP-PCR, we performed nucleotide sequence analysis of COP-PCR products. According to a previous report [17], both *SMN1* and *SMN2* have gene-specific nucleotides in intron 6, with G and A nucleotides at position -44 from exon 7 of *SMN1* and *SMN2*, respectively. As shown in Fig. 4, the COP-PCR product using R111 and *SMN1*-COP had a G nucleotide at position -44 from exon 7, while R111 and *SMN2*-COP had an A nucleotide. These findings show that COP-PCR can separately amplify *SMN1* and *SMN2* exon 7 in a gene-specific way.




Fig. 4 COP-PCR specificity confirmed by sequencing. Nucleotide sequencing analysis confirmed *SMN1*- and *SMN2*-specific amplification. Nucleotide differences in intron 6 (*) and exon 7 (**) prove differential amplification of *SMN1* and *SMN2* by COP-PCR.

COP-PCR with DBS-DNA vs. PCR-RFLP with DNA from freshly collected blood

COP-PCR results using DBS-DNA completely matched those of PCR-RFLP using DNA from freshly collected blood (Table III). COP-PCR results using R111 and *SMN1*-COP also completely matched those of PCR-RFLP (Table III A). Sensitivity and specificity of COP-PCR using DBS-DNA for *SMN1* and *SMN2* exon 7 were 100%. These results suggested that COP-PCR using DBS-DNA is useful for diagnostic screening of SMA patients.

Table III. Comparison between COP-PCR and PCR-RFLP

(A)		PCR-RFLP (freshly collected blood)		Total
		<i>SMN1</i> Exon 7 Deletion	<i>SMN1</i> Exon 7 Non-deletion	
COP-PCR (dried blood)	<i>SMN1</i> Exon 7 Deletion	23	0	23
	<i>SMN1</i> Exon 7 Non-deletion	0	23	23
	Total	23	23	46
sensitivity 1.0, specificity 1.0				
(B)		PCR-RFLP (freshly collected blood)		Total
		<i>SMN2</i> Exon 7 Deletion	<i>SMN2</i> Exon 7 Non-deletion	
COP-PCR (dried blood)	<i>SMN2</i> Exon 7 Deletion	3	0	3
	<i>SMN2</i> Exon 7 Non-deletion	0	43	43
	Total	3	43	46
sensitivity 1.0, specificity 1.0				

DISCUSSION

DBS on filter paper

In this study, we combined DNA extraction from DBS on filter paper with COP-PCR analysis of *SMN1* and *SMN2*, establishing a simple but accurate *SMN1*-deletion detection system that has practical worldwide utility.

We used DBS-DNA as the PCR template, and obtained sufficient DNA for diagnosis of SMA. DBS on filter paper are practical and convenient with regard to handling (involves only spotting and drying blood on filter paper), transport (can be transferred by mail), storage (can be maintained at room temperature, and it is not necessary to store in a refrigerator), and cost (filter paper can be bought at minimal cost).

DBS have been used as biological specimens for more than 50 years, since Guthrie and Susi developed the phenylketonuria screening method to measure phenylalanine levels from DBS on filter paper [6]. Many technologies using DBS have already been developed and applied for medical purposes, including measurement of metabolites (e.g. adrenoleukodystrophy [20]), hormones (e.g. thyroid-stimulating hormone [11]), enzyme activities (e.g. glucose-6-phosphate dehydrogenase [26]), and drugs (e.g. antimalarial drugs [23]).

DBS are now recognized as a good source of DNA, and the combination of PCR with DNA from DBS enables genetic analysis [10, 16]. Molecular screening using DNA from DBS has already been reported for Duchenne/Becker muscular dystrophy and cystic fibrosis [25]. Our findings also support the use of DBS on filter paper as a good source of DNA for disease diagnosis. However, there are limitations to using DBS samples, and in particular, long-term storage of DBS cards may be associated with no PCR amplification, as in our study.

COP-PCR

We show here that COP-PCR can separately amplify the *SMN* genes, *SMN1* and *SMN2*. COP-PCR is a type of allele-specific amplification, in which two oligonucleotide primers compete for DNA annealing. Competitive primers are shorter than usual PCR primers (which are typically 18–25 mer) and identical except for a nucleotide change that is located in the middle of the primer [5]. Amplification with the better-matched primer is favored 100-fold over the mismatched primer [5, 32]. Nucleotide sequencing confirmed that COP-PCR specifically amplified *SMN1* and *SMN2* exon 7. Comparison between COP-PCR and PCR-RFLP demonstrated a complete compatibility of both methods, proving the accuracy of COP-PCR. In addition, *SMN1*-deletion detection by COP-PCR is much faster than that by PCR-RFLP, because COP-PCR has no enzyme-digestion step. As to the required time from the start of PCR to the end of gel electrophoresis separating gene-specific products, COP-PCR takes only 3 hours, while PCR-RFLP takes more than 8 hours.

Conclusion

Here, we have combined DNA extraction from DBS on filter paper with COP-PCR that specifically detects *SMN1* and *SMN2*, and established a new *SMN1*-deletion detection system that is practical for use even in remote areas of the world. Moreover, we also demonstrate that DBS on filter paper are a good source of DNA for disease diagnosis.

DECLARATION OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this paper.

AUTHORS' CONTRIBUTION

NOZOMU KATO and NIHAYATUS SA'ADAH contributed equally to this work.

ACKNOWLEDGMENTS

This study was supported in part by Grants-in-Aid provided by the Research Committee of Spinal Muscular Atrophy, and the Ministry of Education, Culture, Sports, Science and Technology of Japan (Project number 25860860)

REFERENCES

1. **Arkblad, E.L., Darin, N., Berg, K., Kimber, E., Brandberg, G., Lindberg, C., Holmberg, E., Tulinius, M., and Nordling, M.** 2006. Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. *Neuromuscul Disord.* **16**:830-838
2. **Baris, I., Etlik, O., Koksak, V., and Arican-Baris, S.T.** 2010. Rapid diagnosis of spinal muscular atrophy using tetra-primer ARMS PCR assay: Simultaneous detection of *SMN1* and *SMN2* deletion. *Mol Cell Probes* **24**: 138-141.
3. **Coovert, D.D., Le, T.T., McAndrew, P.E., Strasswimmer, J., Crawford, T.O., Mendell, J.R., Coulson, S.E., Androphy, E.J., Prior, T.W., and Burghes, A.H.M.** 1997. The survival motor neuron protein in spinal muscular atrophy. *Hum Mol Genet.* **6**: 1205-1214.
4. **Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T.F., and Wirth, B.** 2002. Quantitative analyses of *SMN1* and *SMN2* based on Real-Time LightCycler PCR: Fast and highly reliable carrier testing and prediction of severity of Spinal Muscular Atrophy. *Am J Hum Genet.* **70**:358-368.
5. **Gibbs, R.A., Nguyen, P., and Caskey, C.T.** 1989. Detection of single DNA base differences by competitive oligonucleotide priming. *Nucleic Acids Res.* **17**:2437-48

6. **Guthrie, R., and Susi, A.** A Simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. 1963. *Pediatrics* **32**: 338-343.
7. **Harada, Y., Sutomo, R., Sadewa, A.H., Akutsu, T., Takeshima, Y., Wada, H., Matsuo, M., and Nishio, H.** 2002. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. *J Neurol.* **249**: 1211-1219.
8. **Harahap, N.I.F., Harahap, I.S.K., Kazynski, H.R., Nurputra, D.K.P., Hartomo, T.B., Pham, H.T.V., Yamamoto, T., Morikawa, S., Nishimura, N., Rusdi, I., Widiastuti, R., and Nishio, H.** 2011. Spinal Muscular Atrophy patient detection and carrier screening using dried blood spots on filter paper. *Genet Test Mol Biomarkers* **16**: 123-129.
9. **Hsieh-Li H.M., Chang, J.G., Jong, Y.J., Wu, M.H., Wang, N.M., Tsai, C.H., and Li, Hung.** 2000. A mouse model for spinal muscular atrophy. *Nat Genet.* **24**: 66-70.
10. **Hue, N.T., Chan, N.D.H., Phong, P.T., Linh, N.T.T., and Giang, N.D.T.** 2012. Extraction of human genomic DNA from dried blood spots and hair roots. *Int J Biosci Biochem Bioinforma.* **2**: 21-26.
11. **Irie, M., and Enomoto, K.** 1975. Measurement of Thyroid-Stimulating Hormone in dried blood spot. *The Lancet* **2**: 1233-4.
12. **Kolb, S.J., and Kissel, J.T.** 2011. Spinal Muscular Atrophy A Timely Review. *Arch Neurol.* **68**: 979-984.
13. **Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., Paslier, D.L., Frézal, J., Cohen, D., Weissenbach, J., Munnich, A., and Melki, J.** 1995. Identification and characterization of a Spinal Muscular Atrophy-determining gene. *Cell* **80**: 155-165.
14. **Lefebvre, S., Burlet, P., Liu, Q., Bertrand, S., Clermont, O., Munnich, A., Dreyfuss, G., and Melki, J.** 1997. Correlation between severity and SMN protein level in spinal muscular atrophy. *Nat Genet.* **16**: 265-269.
15. **McAndrew, P.E., Parsons, D.W., Simard, L.R., Rochette, C., Ray, P.N., Mendell, J.R., Prior, T.W., and Burghes, A.H.M.** 1997. Identification of proximal Spinal Muscular Atrophy carriers and patients by analysis of SMN and SMN gene copy number. *Am J Hum Genet.* **60**: 1411-1422.
16. **McCabe, E.R.B.** 1991. Utility of PCR for DNA analysis from dried blood spots on filter paper blotters. *Genome Res.* **1**: 99-106.
17. **Monani, U.R., Lorson, C.L., Parsons, D.W., Prior, T.W., Androphy, E.J., Burghes, A.H.M., and McPherson, J.D.** 1999. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. *Hum Mol Genet.* **8**: 1177-1183.
18. **Morikawa, S., Harahap, I.S.K., Kaszynski R.H., Yamamoto, T., Pramudya, D.K., Pham, H.T.V., Hartomo, T.B., Lee, M.J., Morioka, I. Nishimura, N., Yokoyama, N., Ueno, Y., Matsuo, M., and Nishio, H.** 2011. Diagnosis of Spinal Muscular Atrophy via High-Resolution Melting Analysis Symmetric Polymerase Chain Reaction without probe: A Screening evaluation for SMN1 deletions and intragenic mutations. *Genet Test Mol Biomarkers* **15**: 677-684.
19. **Munsat, T.L., and Davies, K.E.** 1992. Meeting Report International SMA Consortium Meeting. *Neuromuscul Disord.* **2**: 423-428.
20. **Nishio, H., Kodama, S., Nakajima, T., Matsuo, T., Mio, T., and Sumino, K.** 1987. A Screening method for adrenoleukodystrophy using a dried blood spot on filter paper. *Act Paediatr Jpn.* **29**: 590-594.
21. **Nishio, H., Ishikawa, Y., Lee, M.J., Takeshima, Y., Wada, H., Takada, S., Nakamura, H., Matsuo, M., and Sumino, K.** 1999. High incidence of a survival motor neuron gene/cBCD541 gene ratio of 2 in Japanese parents of spinal muscular atrophy patients: a characteristic background of spinal muscular atrophy in Japan? *J Neurol* **246**: 48-52.
22. **Nurputra, D.K., Lai, P.S., Harahap, N.I.F., Morikawa, S., Yamamoto, T., Nishimura, N., Kubo, Y., Takeuchi, A., Saito, T., Takeshima, Y., Tohyama, Y., Tay, S.K.H., Low, P.S., Saito, K., and Nishio, H.** 2013. Spinal Muscular Atrophy: From Gene Discovery to Clinical Trials. *Ann Hum Genet.* **77**: 435-463.
23. **Patel, K.N., and Patel, J.K.** 2010. A review - qualitative and quantitative analysis of antimalarial drugs and their metabolites in body fluids. *J Curr Pharm Res.* **2** : 5-14
24. **Pearn, J.** 1978. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. *J Med Genet.* **15**: 409-413.
25. **Prior, T.W., Highsmith, W.E., Friedman, K.J., Perry, T.R., Scheuerbrandt, G., and Silverman, L.M.** 1990. A Model for molecular screening of newborns: simultaneous detection of Duchenne/Becker muscular dystrophies and cystic fibrosis. *Clin Chem.* **36**: 1756-1759.
26. **Reclos, G.J., Hatzidakis, C.J., and Schulpis, K.H.** 2000. Glucose-6-phosphate dehydrogenase deficiency neonatal screening: preliminary evidence that a high percentage of partially deficient female neonates are missed during routine screening. *J Med Screening* **7**: 46-51.

27. **Schrank, B., Götz, R., Gunnensen, J.M., Ure, J.M., Toyka, K.V., Smith, A.G., and Sendtner, M.** 1997. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. *Proc Natl Acad Sci.* **94**:9920-9925.
28. **Sutomo, R., Akutsu, T., Takeshima, Y., Nishio, H., Sadewa, A.H., Harada, Y., and Matsuo, M.** 2002. Rapid SMN1 deletion test using DHPLC to screen patients with Spinal Muscular Atrophy. *Am J Med Genet.* **113**:225-226.
29. **Taylor, J.E., Thomas, N.H., Lewis, C.M., Abbs, S.J., Rodrigues, N.R., Davies, K.E., and Mathew, C. G.** 1998. Correlation of SMNt and SMNc gene copy number with age of onset and survival in Spinal Muscular Atrophy. *Eur J Hum Genet.* **6**: 467-474.
30. **Van der Steege, G., Grootscholten, P.M., Van der Vlies, P., Draaijers, T.G., Osinga, J., Cobben, J.M., and Scheffer, H.** 1995. PCR-based DNA test to confirm clinical diagnosis of autosomal recessive spinal muscular atrophy. *The Lancet* **345**: 985-986.
31. **Velasco, E., Valero, C., Valero, A., and Moreno, F.** 1996. Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of cBCD541 and SMA phenotype. *Hum Mol Genet.* **5**: 257-263.
32. **Yen, T., Nightingale, B.N., Burns, J.C., Sullivan, D.R., and Stewart, P.M.** 2003. Butyrylcholinesterase (BCHE) Genotyping for Post-Succinylcholine Apnea in an Australian Population. *Clin Chem.* **49** : 1297-1308